Events & presentations

Upcoming Events
Date Event Details Remind Me
Aug 9, 2017
After 5:00 PM CET
Publication of the Interim Report for the first half 2017
Email

Publication of the Interim Report for the first half 2017

Remind Me

Please sign up for Email alerts.


Sep 8–12, 2017
ESMO 2017 Congress, Madrid, Spain
Email

ESMO 2017 Congress, Madrid, Spain

Remind Me

Please sign up for Email alerts.


Sep 11–13, 2017
Morgan Stanley Global Healthcare Conference, New York, NY, US
Email

Morgan Stanley Global Healthcare Conference, New York, NY, US

Remind Me

Please sign up for Email alerts.


Sep 14, 2017
Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK
Email

Bank of America Merrill Lynch Global Healthcare Conference 2017, London, UK

Remind Me

Please sign up for Email alerts.


Nov 8, 2017
After 5:00 PM CET
Publication of the Interim Report for the first nine months 2017
Email

Publication of the Interim Report for the first nine months 2017

Remind Me

Please sign up for Email alerts.


Dec 31, 2017
Financial calendar year end
Email

Financial calendar year end

Remind Me

Please sign up for Email alerts.


Archived Events
Date Event Details
Jun 22, 2017
J.P. Morgan Cazenove European Healthcare Conference, London, UK
Jun 20–21, 2017
Citi 2017 European Healthcare Conference, London, UK
Jun 13, 2017
8:40 AM PT
Goldman Sachs 38th Annual Global Healthcare Conference, Rancho Palos Verdes, CA, US
Jun 2–6, 2017
ASCO Annual Meeting, Chicago, Illinois, US

To download presentations and select abstracts and posters please click here for our download library. 

Links to abstracts

Daratumumab


Randomized, open-label phase Ib/II study of atezolizumab with or without daratumumab in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)

Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study

Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status


Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX)

Cost effectiveness of carfilzomib (CAR), ixazomib (IXA), elotuzumab (ELO), or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) vs LEN+DEX in relapsed/refractory multiple myeloma (R/R MM)

Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR

Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR)

Comparative efficacy of multiple myeloma therapies for treatment of first relapse: A systematic literature review and network meta-analysis

Trends in survival and costs among US multiple myeloma patients

Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38

Ofatumumab

Updated Results of Frontline Ofatumumab-Hyper-CVAD in Adults with CD20+ Acute Lymphoblastic Leukemia

HuMax-AXL-ADC

GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817)
 

May 11, 2017
4:00 PM CET
Interactive Q&A Session with Genmab's CEO
May 10, 2017
6:00 PM CET
First Quarter 2017 Conference Call
May 10, 2017
After 5:00 PM CET
Publication of the Interim Report for the first quarter 2017
Apr 19, 2017
10th Kempen & Co. Life Sciences Conference, Amsterdam, NL
Mar 28, 2017
Annual General Meeting 2017
Feb 28–Mar 1, 2017
Credit Suisse London One-on-One Healthcare Conference, London, UK
Feb 23, 2017
3:00 PM CET
Interactive Q&A Session with Genmab's CEO
Feb 22, 2017
6:00 PM CET
Full Year 2016 Conference Call
Feb 22, 2017
After 5:00 PM CET
Publication of the Annual Report for 2016
Feb 13, 2017
Deadline for shareholders to submit any items for consideration for the agenda of the Annual General Meeting in writing to the Board of Directors
Jan 11, 2017
5:00 PM PT
35th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US

CEO, Jan van de Winkel, Ph.D., will present a company update at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco at 5:00 PM PST on January 11, 2017 (2:00 AM CET on January 12, 2017).  

Dec 5, 2016
8:00 PM PT
ASH 2016 Data Review meeting

Genmab (OMX: GEN) will hold an ASH 2016 Data Review Meeting on

Monday 5 December 2016 at 8:00 PM Pacific Time (5:00 AM CET / 4:00 AM GMT on 6 December)

The event will take place at the Manchester Grand Hyatt in San Diego, California and will include presentations by external key opinion leaders.
 

You are invited to attend in person or via webcast. The seminar will include data presented at the 2016 American Society of Hematology Annual Meeting (3-6 December).

If you would like to join the meeting in San Diego, please RSVP to Christina Hahner at c.hahner@genmab.com or +1 609 524 0058.

Webcast details will be sent via email prior to the meeting and will also be available on the day of the event, on www.genmab.com

This meeting is NOT an official program of the ASH Annual Meeting.

Dec 3–6, 2016
2016 American Society of Hematology (ASH) Annual Meeting & Exposition, San Diego, CA, US

Visit the Download Library to access presentations and posters presented at the ASH meeting

Links to Abstracts

Daratumumab

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage- Induced ADCP

Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care Therapies in Patients with Heavily Pre-Treated and Highly Refractory Multiple Myeloma

Comparative Effectiveness of Daratumumab Monotherapy Versus a Real-World Historical Control from the Czech Republic in Heavily Pretreated and Highly Refractory Multiple Myeloma Patients

Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor

Overcoming the interference of daratumumab with Immunofixation Electrophoresis (IFE) using an industry-developed DIRA test : Hydrashift 2/4 daratumumab

Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone

High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Daratumumab in combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: results of the IFM2014-04 trial

Ofatumumab

Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

Cost-Effectiveness Analysis of Ofatumumab as a Treatment for Relapsed Chronic Lymphocytic Leukemia in the United States


 

Dec 1, 2016
dbAccess Pharmaceutical and Healtchare Corporate Day, London, UK
Nov 16, 2016
2:00 PM UK
Jefferies 2016 Global Healthcare Conference, London, UK
Nov 14–15, 2016
Bryan Garnier's 4th Annual Healthcare Conference, Paris, FR
Nov 10, 2016
9:00 AM ET
Genmab's 2016 Capital Markets Day

Genmab (OMX: GEN) will host a Capital Markets Day for investors and analysts on

Thursday November 10 at 9:00 AM Eastern Time (3:00 PM CET / 2:00 PM GMT) at the Four Seasons Hotel, 57 E 57th St, New York City.

The meeting will feature a variety of Genmab speakers who will provide updates on Genmab's business including the clinical and pre-clinical pipelines, proprietary next generation antibody technologies and R&D capabilities.

If you would like to join the meeting in New York, please RSVP to Christina Hahner at c.hahner@genmab.com or +1 609 524 0058.

The event will be webcast and details will be available prior to the meeting on www.genmab.com

Nov 3, 2016
4:00 PM CET
Interactive Q&A Session with Genmab's CEO
Nov 2, 2016
6:00 PM CET
Third Quarter 2016 Conference Call
Oct 13, 2016
Hume Brophy Annual Healthcare Investor Conference, London, UK
Sep 14–16, 2016
Bank of America Merrill Lynch Global Healthcare Conference, London, UK
Sep 12–14, 2016
Morgan Stanley Global Healthcare Conference, New York, NY, US
Aug 10, 2016
4:00 PM CET
Interactive Q&A Session with Genmab's CEO
Aug 9, 2016
6:00 PM CET
Second Quarter 2016 Conference Call
Jun 23, 2016
J.P. Morgan London European Healthcare Conference, London, UK
Jun 21–22, 2016
Citi European Healthcare Conference 2016, London, UK
Jun 9–12, 2016
21st Congress of the European Hematology Association (EHA), Copenhagen, Denmark

To download presentations and posters on clincal data, please click here for our download library

Links to abstracts

Daratumumab

An open-label, randomised, Phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX

Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study

Daratumumab monotherapy compared with real-world historical control data in heavily pretreated patients with highly refractory multiple myeloma: an adjusted treatment comparison

Pharmacodynamic relationship between natural killer cells and daratumumab exposure in relapsed/refractory multiple myeloma

Ofatumumab

A phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab-containing therapy (HOMER): results of the interim analysis

Estimating cost effectiveness based on a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukaemia

Updated results of a phase 3 randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) – abstract regarding ofatumumab submitted by Gilead

Idelalisib plus an anti-CD20 antibody in patients with chronic lymphocytic leukemia (CLL) who are HBV core antibody positive: similar patterns of liver test abnormalities – abstract regarding ofatumumab submitted by Gilead

Patterns of idelalisib treatment-emergent lymphocytosis in patients with CLL or SLL – abstract regarding ofatumumab submitted by Gilead

Management of transaminase elevations associated with idelalisib - abstract regarding ofatumumab submitted by Gilead

An evaluation of the CLL-IPI score and comprehensive prognostic factor analysis in patients with r/r CLL in idelalisib phase 3 randomized studies – abstract regarding ofatumumab submitted by Gilead

Discontinuation of idelalisib treatment due to disease progression in patients with relapsed and refractory CLL: an evaluation of outcomes - abstract regarding ofatumumab submitted by Gilead